51.56 0.00 (0.00%)
After hours: 5:19PM EDT
|Bid||51.52 x 900|
|Ask||51.53 x 800|
|Day's Range||51.32 - 51.90|
|52 Week Range||36.28 - 80.66|
|Beta (3Y Monthly)||1.89|
|PE Ratio (TTM)||61.75|
|Earnings Date||Aug 7, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||0.84 (1.63%)|
|1y Target Est||51.67|
Today we will run through one way of estimating the intrinsic value of Perrigo Company plc (NYSE:PRGO) by taking the...
Five years in the making. That is essentially the time it has taken for the S&P 500 to hit a milestone mark at 3,000 for the first time in its history. The stock gauge first closed at 2,000 on Aug. 26, 2014, according to Dow Jones Market Data.
Perrigo Company PLC NYSE:PRGOView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for PRGO with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 24. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $2.32 billion over the last one-month into ETFs that hold PRGO are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
TASE: PRGO) today announced that it has completed the previously announced divestiture of its Animal Health business to PetIQ (PETQ) for $185 million. Perrigo CEO and President Murray S. Kessler stated, "Completing the divestiture of the Animal Health business is an important step in the transformation of Perrigo into a consumer-focused self-care company.
EAGLE, Idaho, July 08, 2019 -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication and wellness company, today announced effective today, it has.
Perrigo (PRGO) completes previously announced acquisition of Ranir. The company raised guidance for adjusted earnings to include accretion of 10 cents from Ranir.
Shares of Dublin-based Perrigo Co. Plc rose 1.5% in premarket trade Wednesday after the company said the U.S. Food and Drug Administration had approved a development partner's marketing application for a generic version of Metrogel-Vaginal, a treatment for bacterial vaginosis. The generic was developed in partnership with Capstone Development Solutions, a unit of Water Street Healthcare Partners, and Perrigo will get full ownership of the application within the next 30 days. Annual market sales for Metrogel-Vaginal for the 12 months ending May 2019 were around $100 million, Perrigo said, and the company plans to start selling the drug immediately after getting ownership of the application. Shares of the company have gained 27.4% in the year to date through Tuesday, while the S&P 500 has gained 18.6%.
TASE: PRGO) today announced its product development partner received final approval from the U.S. Food and Drug Administration for its AB-rated Abbreviated New Drug Application ("ANDA") referencing Metrogel-Vaginal® (metronidazole vaginal gel 0.75%). Perrigo will acquire full ownership of the ANDA under a pre-existing arrangement with its partner within 30 days and anticipates launching this product immediately thereafter. The product is manufactured by Perrigo and was developed through its partnership with Capstone Development Solutions, a company of Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. Perrigo Executive Vice President and President Rx Pharmaceuticals, Sharon Kochan stated, "This launch exemplifies Perrigo's commitment to developing and launching products within the extended topicals category.
Perrigo Company (NYSE: PRGO ) has acquired Ranir Global Holdings, a supplier of oral self-care products for $750 million in cash. Perrigo also adjusted its FY2019 earnings guidance, from $3.75-$4.05 including ...
Shares of Perrigo Co. Plc rose 2% in premarket trade Tuesday after the company raised its adjusted full-year EPS guidance to between $3.75 and $4.05 from between $3.65 and $3.95. The Dublin-based pharmaceutical company said the 10-cent boost came from its $750 million cash acquisition of oral-care products company Ranir Global Holdings LLC, which Perrigo said had successfully closed. Shares of Perrigo have gained 25% in the year to date through Monday, while the S&P 500 has gained 18.3%.
- Advances transformation to a consumer-focused, self-care company - Raises 2019 non-GAAP ("adjusted") diluted EPS guidance to between $3.75 - $4.05 (1), which includes accretion of $0.10 from ...
Is Perrigo Company plc (NYSE:PRGO) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]
Dividend paying stocks like Perrigo Company plc (NYSE:PRGO) tend to be popular with investors, and for good reason...
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Consistent with Sol-Gel’s prior agreements with Perrigo, Perrigo will seek regulatory approval with the U.S. Food and Drug Administration (“FDA”) for these generic product candidates. If approved by the FDA, Perrigo has agreed to commercialize the generic product candidates in the United States.
NEW YORK , May 22, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
TASE: PRGO) today announced its partner received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application (ANDA) referencing Voltaren® Gel, 1% (diclofenac sodium topical gel, 1%). Perrigo will acquire full ownership of the ANDA under a pre-existing arrangement with its partner within 30 days. Perrigo will manufacture diclofenac sodium topical gel 1% in its plant in Israel.
Every investor in Perrigo Company plc (NYSE:PRGO) should be aware of the most powerful shareholder groups. Large...
U.S. stocks fell on Wednesday, as a clutch of weak economic data from the United States and China sparked worries of slowing global growth against the backdrop of a bitter trade dispute that has roiled financial markets. Domestic data showed retail sales unexpectedly fell in April as households cut back on purchases of motor vehicles and a range of other goods, and another report showed declining output of cars and machinery led to a surprise fall in U.S. factory production for April. Meanwhile data from China also showed surprisingly weak growth in retail sales and industrial output for April, adding pressure on the country to roll out more stimulus.
Wall Street was set to open lower on Wednesday, as a surprise fall in domestic retail sales and underwhelming data from China raised growth concerns, while investors waited for more developments on the U.S.-China trade dispute. Government data showed U.S. retail sales unexpectedly fell in April as motor vehicle purchases slumped, while data from China also showed surprisingly weak growth in retail sales and industrial output for April, adding pressure on Beijing to roll out more stimulus. "The U.S. retail sales report is clearly disappointing.